CHMP Issues Positive Opinion for Teva's DuoResp Spiromax

Teva Pharmaceuticals announced it has received opinion from theEuropean Medicines Agency's(EMA)Committee for Medicinal Products for Human Use(CHMP) for marketing authorization of its treatment DuoResp®Spiromax®(budesonide & formoterol fumarate dihydrate) inhalation powder.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news